Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty 100 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Laboratories has received a letter dated March 5, 2026, from the U.S. Department of Justice (DOJ), Criminal Division, Fraud Section, informing the company that the DOJ has closed its inquiry under the U.S. Foreign Corrupt Practices Act (FCPA). The DOJ has not recommended any enforcement action against the company. This follows a similar communication from the U.S. Securities and Exchange Commission (SEC) on February 24, 2026, which also closed its investigation without recommending enforcement. The investigations originated from an anonymous complaint received in November 2020 alleging improper payments to healthcare professionals in Ukraine and potentially other countries.
This is a significant positive development for Dr. Reddy's shareholders, as it removes a long-pending regulatory overhang related to U.S. anti-corruption laws. Closure of both the SEC and DOJ inquiries without enforcement action reduces legal risk, potential financial penalties, and reputational damage, which should be viewed favorably by the market.